Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessMarketsLupin's much-awaited approval for gSpiriva is here; will it change the drug maker’s fortunes?

    Lupin's much-awaited approval for gSpiriva is here; will it change the drug maker’s fortunes?

    The market has cheered the development, which comes ahead of the timeline set by Lupin's management at its March quarter earnings call, much more needs to be done before the company's fortunes turn around meaningfully.

    Vaibhavi Ranjan
    June 22, 2023 / 07:58 IST
    Lupin, in the recent years has witnessed a consistent pressure on margins which has been a drag on its financials, hence, analysts had pegged their hopes on crucial drug launches, like that of gSpiriva to improve the company's profitability.
    • PRO Panorama

      Moneycontrol Pro Panorama | Of balance sheets and innovation

      Nov 28, 2025 / 03:03 PM IST

      Moneycontrol Pro Panorama November 28 edition: India’s employment paradox decoded, Gold is glittering and equity is holding up, ...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts